Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling

Oncotarget

Volumn 7, Issue 10, 2016, Pages 10773-10787

  Hung, Ching Hsia ^a   Chan, Shih Hung ^b   Chu, Pei Ming ^c   Lin, Huei Chen ^a,d   Tsai, Kun Ling ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Shu Zen Junior College of Medicine and Management   (Taiwan)

Author keywords

Endothelial dysfunction; Gerotarget; Metformin; OxLDL; SIRT1

Indexed keywords

ADENYLATE KINASE; ADENYLATE KINASE ALPHA; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN; OLR1 PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOAVAILABILITY; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; OXIDATION REDUCTION REACTION; VASCULAR ENDOTHELIUM;

ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, LDL; METFORMIN; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; SIRTUIN 1; UP-REGULATION;

EID: 84962018962     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7387     Document Type: Article

References (55)

1. Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of. peripheral arterial disease? Atherosclerosis. 2008 Mar;197:1-11.
2. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1005-28.
3. Papaharalambus CA and Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. 2007; 17:48-54.
4. Herman AG and Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J. 2005; 26:1945-1955.
5. Lei J, Gu X, Ye Z, Shi J and Zheng X. Antiaging Effects of Simvastatin on Vascular Endothelial Cells. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2012.
6. Orecchia A, Scarponi C, Di Felice F, Cesarini E, Avitabile S, Mai A, Mauro ML, Sirri V, Zambruno G, Albanesi C, Camilloni G and Failla CM. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PloS one. 2011; 6:e24307.
7. Kugel S and Mostoslavsky R. SIRT1 activators: the evidence STACks up. Aging (Albany NY). 2013; 5:142-143.
8. Zarzuelo MJ, Lopez-Sepulveda R, Sanchez M, Romero M, Gomez-Guzman M, Ungvary Z, Perez-Vizcaino F, Jimenez R and Duarte J. SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochemical pharmacology. 2013; 85:1288-1296.
9. Kitada M, Kume S, Imaizumi N and Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes. 2011; 60:634-643.
10. Pazienza V, Borghesan M, Mazza T, Sheedfar F, Panebianco C, Williams R, Mazzoccoli G, Andriulli A, Nakanishi T and Vinciguerra M. SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation. Aging (Albany NY). 2014; 6:35-47.
11. Kao CL, Chen LK, Chang YL, Yung MC, Hsu CC, Chen YC, Lo WL, Chen SJ, Ku HH and Hwang SJ. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. Journal of atherosclerosis and thrombosis. 2010; 17:970-979.
12. Jia Y, Gao P, Chen H, Wan Y, Zhang R, Zhang Z, Yang R, Wang X, Xu J and Liu D. SIRT1 suppresses PMA and ionomycin-induced ICAM-1 expression in endothelial cells. Science China Life sciences. 2013; 56:19-25.
13. Guo H, Chen Y, Liao L and Wu W. Resveratrol Protects HUVECs from Oxidized-LDL Induced Oxidative Damage by Autophagy Upregulation via the AMPK/SIRT1 Pathway. Cardiovascular drugs and therapy. 2013; 27:189-198.
14. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992; 15:755-772.
15. Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:550-554.
16. Bailey CJ and Turner RC. Metformin. N Engl J Med. 1996; 334:574-579.
17. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108:1167-1174.
18. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M and Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310:1642-1646.
19. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120:2355-2369.
20. Owen MR, Doran E and Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000; 348 Pt 3:607-614.
21. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275:223-228.
22. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B and Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011; 54:3101-3110.
23. Hawley SA, Ross FA, ChevtzoffC, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM and Hardie DG. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell metabolism. 2010; 11:554-565.
24. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012; 122:253-270.
25. Xu W, Deng YY, Yang L, Zhao S, Liu J, Zhao Z, Wang L, Maharjan P, Gao S, Tian Y, Zhuo X, Zhao Y, Zhou J, Yuan Z and Wu Y. Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. Translational research. 2015; 166:451-458.
26. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, Toussaint L, Dequiedt F, Mostoslavsky R, Schmidt MH, Zimmermann B, Brandes RP, Mione M, Westphal CH, Braun T, Zeiher AM, et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature. 2011; 473:234-238.
27. Tsai KL, Chen LH, Chiou SH, Chiou GY, Chen YC, Chou HY, Chen LK, Chen HY, Chiu TH, Tsai CS, Ou HC and Kao CL. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. Molecular nutrition & food research. 2011; 55 Suppl 2:S227-240.
28. Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q, Subbulakshmi V, Feldman GM, Wientjes FB and Cathcart MK. Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes. Journal of immunology. 2004; 173:5730-5738.
29. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, Pagnin E, Fadini GP, Albiero M, Semplicini A and Avogaro A. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arteriosclerosis, thrombosis, and vascular biology. 2007; 27:2627-2633.
30. Taye A, Saad AH, Kumar AH and Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. European journal of pharmacology. 2010; 627:42-48.
31. Hung CH, Chan SH, Chu PM and Tsai KL. Homocysteine facilitates LOX-1 activation and endothelial death through the PKCbeta and SIRT1/HSF1 mechanism: relevance to human hyperhomocysteinaemia. Clinical science. 2015; 129:477-487.
32. Amaravadi R and Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest. 2005; 115:2618-2624.
33. Sakamoto N, Ishibashi T, Sugimoto K, Sawamura T, Sakamoto T, Inoue N, Saitoh S, Kamioka M, Uekita H, Ohkawara H, Suzuki K, Teramoto T, Maruyama Y and Takeishi Y. Role of LOX-1 in monocyte adhesion-triggered redox, Akt/eNOS and Ca2+ signaling pathways in endothelial cells. J Cell Physiol. 2009; 220:706-715.
34. Pillarisetti S. A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat Cardiovasc Drug Discov. 2008; 3:156-164.
35. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF and Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007; 100:1512-1521.
36. Stein S and Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle. 2011; 10:640-647.
37. Ota H, Akishita M, Eto M, Iijima K, Kaneki M and Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol. 2007; 43:571-579.
38. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23:2369-2380.
39. Harja E, Chang JS, Lu Y, Leitges M, Zou YS, Schmidt AM and Yan SF. Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis. FASEB J. 2009; 23:1081-1091.
40. Shi Y, Cosentino F, Camici GG, Akhmedov A, Vanhoutte PM, Tanner FC and Luscher TF. Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31:2090-2097.
41. Dong Y, Zhang M, Wang S, Liang B, Zhao Z, Liu C, Wu M, Choi HC, Lyons TJ and Zou MH. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes. 2010; 59:1386-1396.
42. Jain AK, Mehra NK and Swarnakar NK. Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities. Current pharmaceutical design. 2015; 21:4441-4455.
43. Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L, Forstermann U and Li H. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). Journal of physiology and pharmacology. 2009; 60 Suppl 4:111-116.
44. Mehta JL, Chen J, Hermonat PL, Romeo F and Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006; 69:36-45.
45. Chen XP, Xun KL, Wu Q, Zhang TT, Shi JS and Du GH. Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: role of reactive oxygen species. Vascul Pharmacol. 2007; 47:1-9.
46. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L and Nenseter MS. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. The Journal of nutrition. 2003; 133:3588-3591.
47. Sugimoto K, Ishibashi T, Sawamura T, Inoue N, Kamioka M, Uekita H, Ohkawara H, Sakamoto T, Sakamoto N, Okamoto Y, Takuwa Y, Kakino A, Fujita Y, Tanaka T, Teramoto T, Maruyama Y, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res. 2009; 84:127-136.
48. Stein S, Schafer N, Breitenstein A, Besler C, Winnik S, Lohmann C, Heinrich K, Brokopp CE, Handschin C, Landmesser U, Tanner FC, Luscher TF and Matter CM. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging (Albany NY). 2010; 2:353-360.
49. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K and Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. International journal of molecular medicine. 2005; 16:237-243.
50. Chong ZZ, Lin SH and Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. Journal of cerebral blood flow and metabolism. 2004; 24:728-743.
51. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:854-865.
52. Ghosh S, Lakshmanan AP, Hwang MJ, Kubba H, Mushannen A, Triggle CR and Ding H. Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. Biochemical pharmacology. 2015; 98:412-421.
53. Eriksson L and Nystrom T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular diabetology. 2014; 13:152.
54. Arunachalam G, Samuel SM, Marei I, Ding H and Triggle CR. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. British journal of pharmacology. 2014; 171:523-535.
55. Tsai KL, Huang YH, Kao CL, Yang DM, Lee HC, Chou HY, Chen YC, Chiou GY, Chen LH, Yang YP, Chiu TH, Tsai CS, Ou HC and Chiou SH. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. The Journal of nutritional biochemistry. 2012; 23:458-468.